Knowledge and Attitudes Towards Clinical Trials Among Women with Ovarian Cancer: Results of The Acto Study

Paola Mosconi (mosconi@marionegri.it)
IRCCS Istituto di Ricerche Farmacologiche Mario Negri

Anna Roberto
IRCSS: Istituto Di Ricerche Farmacologiche Mario Negri

Nicoletta Cerana
ACTO Alleanza contro il tumore ovarico Onlus

Nicoletta Colombo
Istituto Europeo di Oncologia

Florence Didier
Istituto Europeo di Oncologia

Maurizio D’Incalci
IRCCS Humanitas Research Hospital

Domenica Lorusso
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Fedro Alessandro Peccatori
Istituto Europeo di Oncologia

Network of Clinicians Participants
Istituto Europeo di Oncologia

Research

Keywords: Ovarian Cancer, Knowledge, Advocacy group, Survey

Posted Date: October 5th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-944644/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Although there are several initiatives by research groups, regulatory authorities, and scientific associations to engage citizens/patients in clinical research, there are still obstacles to participation. Among the main discouraging aspects are incomplete understanding of the concepts related to the clinical trial, and the scant, sometimes confused, explanations given. The aim of this observational, cross-sectional multicenter study is to investigate knowledge, attitudes and trust in clinical research.

We conducted a survey among women with ovarian cancer at their first follow-up visit or first therapy session, treated in centers belonging to the Mario Negri Gynecologic Oncology (MaNGO) and Multicenter Italian Trials in Ovarian Cancer (MITO) groups. A questionnaire on knowledge, attitudes and experience was assembled ad hoc after a literature review and a validation process involving patients of the Alliance against Ovarian Cancer (ACTO).

Results

From 25 centers 348 questionnaire were collected; 73.5% of responders were 56 years or older, 54.8% had a high level of education, more than 80% had no experience of trial participation. Among participants 59% knew what clinical trials are and 71% what the informed consent is. However more than half did not know the meaning of the term randomization. More than half (56%) were in favor of participating in a clinical trial, but 35% were not certain. Almost all responders acknowledged the doctor’s important role in decision-making. Patients associations were recognized as playing a powerful role in the design and planning of clinical trials.

Conclusions

This study helps depict the knowledge and attitudes of women with ovarian cancer in relation to clinical trial, suggesting initiatives aimed at improving trials’ culture, literacy and compliance, and fresh ways of communication between doctors and patients.

Introduction

Advances in medicine and healthcare are based on research, firstly in laboratories and then through clinical studies. Currently there are several initiatives by research groups, regulatory authorities, patients’ advocacy groups or scientific societies to move citizens and patients closer to the discussion of research priorities and partnership, mainly based on the assumption that where there is clinical research the patients’ care is better. Various materials, websites, tutorials and videos, have been developed in different languages for lay people and patients aimed to explain the fundamental concepts of clinical trials and encourage awareness and participation. There are also other interesting experiences promoting active involvement and partnership.
Nevertheless, among the obstacles that researchers generally encounter in presenting and conducting clinical trials, the involvement and adhesion of patients stand out\textsuperscript{8,9} as well as the scant knowledge citizens and patients have about clinical research.\textsuperscript{10–12} Other discouraging aspects are the incomplete understanding of the concepts related to the proposed study, in particular randomization methods, and the scarce, sometimes confusing, explanations received from the doctor or healthcare staff presenting the study. Finally, there is fear of adverse events given the uncertainty about the new therapy, the possibility of direct or indirect costs or additional medical visits - which may be problematic for the patients and the caregiver - or the feeling of being subject to an experiment.\textsuperscript{13,14} Among the main reasons for participation are the altruistic feeling of being able to improve health care for other patients and society, access to free, innovative therapies and being carefully monitored.\textsuperscript{15,16}

Knowledge, attitudes and experience related to clinical research, particularly randomised clinical trials (RCT) which are recognised as the best methodological approach to reach hard, reproducible results, are not in generally investigated among lay people and participants in clinical research,\textsuperscript{17,18} especially ovarian cancer patients despite fruitful research in this area. Ovarian cancer is 10th female neoplasms, and remains one of the biggest killers, with its high mortality: five-year survival does not exceed 40\%, 31\% at ten years.\textsuperscript{19}

The Alliance against Ovarian Cancer (ACTO) is an Italian non-profit organization, with seven regional branches and more than a thousand associates that aims to create a strong alliance between patients, researchers, and doctors to fight ovarian cancer (https://www.acto-italia.org/it). ACTO decided to investigate issues related to trial participation, considering that despite the low incidence of ovarian cancer, clinical research is making constant progress through collaborative research groups.

The aims of this observational, cross-sectional multicenter study are to investigate how familiar clinical research is, particularly RCT, to women with ovarian cancer and how they react to the proposal to participate in a clinical trial. The following areas will be considered: knowledge and understanding, confidence, obstacles and reasons for participating, and satisfaction with the information received. An ad hoc picture of the knowledge, attitudes and experience of these patients with clinical trials will be useful in order to promote trial participation and to improve the general perception of research among personally involved women and, consequently, in their families and in society.

**Material And Methods**

Italian centers belonging to the MaNGO-Mario Negri Gynecologic Oncology\textsuperscript{20} and MITO-Multicenter Italian Trials in Ovarian Cancer\textsuperscript{21} groups were invited to participate. Women with a confirmed diagnosis of epithelial ovarian cancer, signing informed consent, were included in the study at the first follow-up visit and/or at the first therapy session. Exclusion criteria were women not understanding Italian, those with life expectancy less than six months and women in phase 1 trials. Each participant center was asked to present the study to eligible women, to collect signatures for informed consent, and to deliver the first questionnaire. After three months, the coordinator center mailed the follow-up questionnaire to women
willing to participate an RCT and giving a consent to be further contacted in order to find out their direct experience.

The study started in March 2019, and finished in September 2020 after several months of delay due to the SARS-CoV2 pandemic.

**Questionnaire**

The questionnaire was developed starting from literature, and through a process involving researchers, clinicians and ACTO regional branches (Puglia, Campania, Lombardia, Piemonte, and Lazio) (Supplementary 1).

**Item generation**

In 2018, a literature search restricted to papers published after 1 January 2000 identified 125 articles, 19 of them eligible according to the protocol, and four others were added by references. As no questionnaire fitted the protocol we collected questions from selected articles and set out a comparative table according to three domains: knowledge, attitudes and experience. Depending on the frequencies and relevance we selected a set of questions and adapted them to the Italian setting with simple and direct language.

**Validity of content**

A pilot test among ten research experts in the Coordinator Center evaluated the completeness of each domain (irrelevant questions, and aspects not taken into account), and the clarity of the questions. Seven proposed re-formulating of some questions and layout changes. The proposed changes were discussed and implemented, leading to the second version of the two questionnaires.

**Test (field-test)**

New versions were discussed during a meeting of representatives of ACTO branches. Participants received a copy of the questionnaires in advance together with a form to collect comments and feedback on completeness, clarity, timing and difficulty (based on the EORTC Debriefing Form model). All feedbacks were discussed during the meeting. This led to revision of the questionnaires: two questions were added in the first questionnaire and revisions were made to some questions and answers in both the first and second questionnaires. Finally, the last versions of the questionnaires were sent to a convenience sample of target women identified by ACTO representatives’ group. No significant request emerged from these questionnaires, and only one question was modified.

After discussion with the ACTO representatives’ group, we decided to use a paper questionnaire rather than a web tool, considering it the best method to ensure greater adherence to the study, facilitating the participation of women who are not used to technological tools.
Sample size

In view of descriptive nature of the study, no statistical hypothesis was formulated and no formal calculation of the sample size. A recruitment period of six months was established.

Statistical analyses

Descriptive analyses were conducted using SAS statistical software, version 9.4 that allows crossing variables according to several criteria. A statistical test (p-value) was used only for results showing a significant trend, using alpha of 0.05.

Results

Were collected 359 questionnaires from 25 participant centers; 348 were included in the analysis as 11 had to be excluded: 1 withdrew consent, 3 were collected after the end of the study, and 7 were not from patients with ovarian cancer. Among the 80 eligible responders for follow up questionnaire, 62 women were reached as they provided a valid address; 17 follow-up questionnaires were collected but their results are not included in this article.

Table 1 presents the characteristics of the responders. Most of responders were 56 years or older, half of responders had a high school level of education, and most of the women did not have paid work; 56.3% have been diagnosed with ovarian cancer in the last two years, and more than 80% had not taken part in clinical trial in the past, but 26% had been invited to enter a clinical trial in the previous three months.
Table 1  
– Characteristics of 348 responders

| Age                        | No. (%) * |
|----------------------------|-----------|
| Less than 55 years         | 92 (26.5) |
| 56-65 years                | 124 (35.6)|
| More than 66 years         | 132 (37.9)|

| Education                  | No. (%) * |
|----------------------------|-----------|
| Elementary or lower middle | 157 (45.2)|
| High school or degree      | 190 (54.8)|

| Employment                 | No. (%) * |
|----------------------------|-----------|
| Paid work (full or part-time) | 95 (28.9)|
| No paid work (retired, housewife other) | 234 (71.1)|

| Work in a healthcare profession | No. (%) * |
|---------------------------------|-----------|
| Yes                             | 21 (6.2)  |
| No                              | 316 (93.8)|

| Year of diagnosis of ovarian cancer | No. (%) * |
|------------------------------------|-----------|
| 2019-2020                           | 196 (56.3)|
| Before 2019                         | 152 (43.7)|

| In the past have you ever been invited to take part in a clinical trial? | No. (%) * |
|------------------------------------------------------------------------|-----------|
| Yes                                                                    | 40 (11.6) |
| No                                                                     | 305 (88.4)|

| Have you been invited to participate in a randomized clinical trial in the past three months? | No. (%) * |
|-----------------------------------------------------------------------------------------------|-----------|
| Yes                                                                                           | 88 (26.0) |

*Discrepancies in the total are due to missing values (less than 6%)
The best-known aspect of clinical research was informed consent. About 60% of women had read about clinical trial on the internet, in magazine, or on tv or had discussed with their physician and about 60% knew that ethics committee authorisation was required before starting a trial. Only 34.9% knew the meaning of randomization (Table 2). These percentages were higher in the small sample of 21 women working in health setting. Education and a longer history of illness were associated with more knowledge about clinical research (Supplementary 2).
Table 2  
Knowledge about clinical trials

| Question                                                                 | No. (%) |
|-------------------------------------------------------------------------|---------|
| Have you ever read on the Internet or in newspapers, heard on television or discussed with your doctor anything about a "clinical study" or "clinical trial"? |         |
| Yes                                                                     | 202 (59.1) |
| No                                                                      | 140 (40.9) |
| Do you know what the term “randomization” means referring to the investigation of a new drug or medical procedure? |         |
| Yes                                                                     | 120 (34.9) |
| No                                                                      | 224 (65.1) |
| Have you ever heard about "informed consent" in relation to clinical research? |         |
| Yes                                                                     | 247 (71.8) |
| No                                                                      | 97 (28.2)  |
| Do you know that starting a clinical trial requires the approval of an ethics committee, made up of people with different skills, who assess the scientific validity, quality, and feasibility of the trial? |         |
| Yes                                                                     | 202 (59.4) |
| No                                                                      | 138 (40.6) |

*Discrepancies in the total are due to missing values (less than 3%)

Six aspects were assessed to evaluate attitudes toward clinical trials (Table 3). In general responders agreed that clinical trials benefit patients and society (91.5%), and that the doctor has a very important part in the decision (90.3%). Half of responders said “I don’t know” when considering the risk/benefit ratio, and whether to participate, themselves or a relative or friend. Responders acknowledged that the publication of all the results, positive or negative, was necessary in scientific articles and lay publications. The level of education influenced particularly the question about on publishing all the data, 71.9% vs 85.5% in the more educated sample, while the duration of illness influenced all the responses, also lowering the rates of "I don't know".
### Table 3
– Attitudes towards clinical trials

| Area                                                                 | Strongly agree/Agree | I don't know | Strongly disagree/ Disagree |
|----------------------------------------------------------------------|----------------------|--------------|----------------------------|
| **Clinical trials benefit patients and society**                     | 202 (91.5)           | 27 (8.2)     | 1 (0.3)                    |
| **The risks of participating in a clinical trial outweighs the potential benefits** | 36 (11.4)            | 171 (54.1)   | 109 (34.5)                 |
| **The doctor is important in the decision to participate in a clinical trial** | 290 (90.3)           | 23 (7.2)     | 8 (2.5)                    |
| **If asked, I would be in favor of participating in a clinical trial** | 180 (56.8)           | 118 (35.2)   | 19 (6.0)                   |
| **I would also encourage a relative or friend to participate in a clinical trial** | 176 (55.4)           | 118 (37.1)   |                            |

*Discrepancies in the total are due to missing values (than 10%)
| Strongly disagree/ Disagree | 24 (7.5) |
|----------------------------|---------|
| **All clinical trial results, positive or negative, must be made public in scientific articles and lay publications** | |
| Strongly agree/Agree | 257 (77.9) |
| I don't know | 55 (16.7) |
| Strongly disagree/ Disagree | 18 (5.4) |
| *Discrepancies in the total are due to missing values (than 10%)* | |

Full disclosure of the advantages and disadvantages, with clearly-defined reference group of healthcare professionals are the most important aspects to consider to participate in a clinical trial. Also relevant are the usefulness of data collected for future patients, and a clear description of duties. Participants are also particularly interested in the purpose of data collection and storage of the data (Table 4).
Table 4  
– Clinical trials and participation

| Indicate the answers you consider most important before taking part in a clinical trial (3 answers possible) | No. (%) |
|-------------------------------------------------------------------------------------------------------------|---------|
| Full information on the advantages and disadvantages                                                    | 296 (30.2) |
| Physicians or health professionals for reference                                                            | 234 (23.8) |
| Confidence that the results will be useful for future patients                                            | 193 (19.7) |
| A clear description of how it will be conducted and what participation implies (visits, extra costs, etc.) | 190 (19.4) |
| Information material to consult independently                                                               | 39 (3.9) |
| Insurance coverage                                                                                         | 14 (1.4) |
| Who finances the study (non-profit organizations or associations, pharmaceutical companies, private companies, etc.) | 15 (1.5) |

| For greater security in the use of personal data collected during a clinical trial, you need to know ... (2 answers possible) | No. (%) |
|-------------------------------------------------------------------------------------------------------------------------------|---------|
| For what purpose the data is collected                                                                                       | 221 (34.9) |
| By whom, where, and for how long it will be stored                                                                           | 134 (21.2) |
| Who has access to the data                                                                                                    | 94 (14.8) |
| How participants’ privacy will be ensured                                                                                      | 88 (13.9) |
| Consent will be required to use the data in other studies                                                                       | 56 (8.8) |
| How to modify or withdraw consent to use of data at any time                                                                 | 40 (6.3) |

Most responders (91.5%) thought it right that doctors - when they have data in favor of a new treatment but not certainty compared to one already available - ask patients to participate in a clinical trial. Responders thought that the good of the patient and community (47.2% of preferences), together with the progress of science and medicine (42.9% preferences), were the most important reasons for a doctor to
invite a patient to take part in a trial, compared to difficulties in treating the patient (5.6%) or personal gain (2.4%) or pharmaceutical company interests (1.8%).

Regarding the patients’ associations, 71.2% of responders agreed that their involvement in design and planning is important, recognising a role in providing information and facilitating participation more than discussing the trial plan or the results (Table 5).

Table 5
– Involvement of patients’ association in designing and planning clinical trials

| Should the representatives of citizens and patients be actively involved in the design and planning of a clinical trial? | No. (%) |
|---|---|
| Yes | 237 (71.2) |
| No | 96 (28.8) |
| Missing | 15 |

If Yes, what role have representatives of citizens and patients (2 answers possible)

| Role | No. (%) |
|---|---|
| Improve the information given to patients about the trial | 96 (20.9) |
| Facilitate patients’ participation in the trial | 93 (20.3) |
| Make suggestions for clinical trials of real benefit to patients | 91 (19.8) |
| Help with financing the trial | 56 (12.2) |
| Discuss the clinical trial plan to make it better | 55 (11.9) |
| Communicate the trial results | 39 (8.5) |
| Be the spokesman for patients during analysis and discussion of the results | 29 (6.3) |

Finally, 80 (90.9%) of the 88 women invited to participate in a clinical trial during this study agreed. Among their reasons they cited confidence in the doctor (32% of preferences), benefits to society (22.9%), access to new therapies that are not otherwise available (21.7%), and because the clinical trial offers the best possible treatment (10.2%).
Discussion

This study gives a snapshot of the knowledge and attitudes of women with a history of ovarian cancer on clinical trials. Most of the participants know what the clinical trials and informed consent are nevertheless more than half do not know the meaning of the term randomization, and are unable to evaluate the benefit-risk ratio of participation. Half of the participants were in favor of participating and about a third were not certain. In case of clinical uncertainty about the best treatment, doctors have a right to ask a patient to participate in a clinical trial and have - as said by almost all responders - an important role in the decision-making. Patients’ associations are recognized as having a powerful role in the design and planning of clinical trials. Only a small percentage of women in this study had been asked to participate in a trial in the past, even among those with a longer history of the disease. This is in line with a survey by the World Ovarian Cancer Coalition which reported a 12% of participation in clinical trials. However, in our sample, out of the 88 women invited to participate in a trial in the past three months, only eight had refused.

In accordance with the mission of ACTO, these results will lead to important advocacy to promote more research in this specific area of gynecologic oncology and to invite more women to participate in clinical research. Population-wide action to raise the awareness of clinical trials is also needed, possibly jointly among cancer patient organizations. The knowledge about clinical research and trials reflects the need for greater attention to health literacy and empowerment. The promotion of clinical research and trials among healthy people, before they become patients, is also needed to facilitate participation in clinical research and decisions.

In general, there is a positive attitude towards clinical research and trials, recognizing the benefits for patients and society; however, responders showed uncertainty when evaluating the balance between risk and benefits. Personal decisions to participate, themselves or a relatives or friends, showed a high level of indecision. In line with other experiences, these results suggest the need to boost confidence in clinical research, and the greater involvement of clinicians when a trial is proposed to patients. The majority in our sample think doctors play an important role in a decision, and confidence in the doctor is the first reason to participate.

Uncertainty about the results of experimental treatments, associated with fear of death, might explain both hesitancy and a passive role in decisions. It is well known that a cancer diagnosis and the related complex decisions, like participation in a trial, can create emotional stress or anxiety. Cancer is often associated with uncertainty and fear of death and the request to participate in a trial may increase anxiety; both anxiety and depression are associated with difficulty in making decisions. Furthermore, anxiety is linked to increased engagement in threat-avoidance behaviors, and depression is linked to reduced engagement in reward-seeking behaviors. Emotions are potent, pervasive, predictable, sometimes harmful and sometimes beneficial drivers of decisions. Across different domains, important regularities appear in the mechanisms through which emotions influence judgments and choices.
increased awareness of emotions may help putting them to best use and reduce their influence as a bias in shared decisions.35

Our study confirms that it is still necessary to improve and implement the culture of shared decision-making in oncology. In a review, Covvey et al.36 identified barriers to shared decision-making: uncertainty in the treatment decision, concern regarding adverse effects, and poor physician communication. They describe themes for facilitators for shared decision-making including the physician's consideration of the patient's preferences, physician's positive actions and behavior, and the use or encouragement of support systems. As indicated in our study, the patient-physician relationship can influence patients' preferences for and processing of information. Informed decision can be facilitated by considering each single patient's knowledge, values, and emotional and cognitive decisional skills. Considering all these factors can therefore be useful to improve the shared decision-making, possibly increasing patients' participation in clinical trials.

The role of associations is widely recognised, in line with a general consensus in the literature and among cooperative groups about partnership in clinical research discussions and projects.37 Partnership with patients' representatives may mitigate the difficulties due to poor retention rate, impact, low level and clinical significance of the study.38 Patient's associations, besides promoting comprehensive scientific information and offering psychological support, foster clinical research based on patients' needs, helping develop feasible, good-quality clinical trials.39,40

This study has some limitations. First of all, the representativeness of the sample collected: the participating centers are all centers of excellence, specialized in ovarian cancer treatment and participating in clinical research through national or international multicenter trials. This may have led women to have more confidence in the study, and in the proponent physicians involved. Secondly, not all the centers invited participated and the numbers of patients involved by each center ranged between 1 to 45, and there is no information about patients that refused to participate. While it is true that the pandemic influenced the accrual of patients, it is also true that this type of study, academic, cross-sectional, observational, tends to be less attractive for clinicians than interventional trials. Thirdly, the preparation of local documents for the evaluation by the Ethics Committee influenced the participation of several centers. On average, 181 days were required for approval, with a range between 66 and 362 days, thus further reflecting the difficulties in coordinating this type of study. Finally, the data collected with the second questionnaire was too limited for any data analysis.

In conclusion, knowledge and attitudes towards participation in clinical research are important for their success and implications. These results add useful information to a larger project aimed at improving the culture of clinical trials and larger-scale awareness of this topic. As regard shared decision-making, Covvey et al.36 showed that the most common cancers studied are breast and prostate, and the strength of this study is to provide information about ovarian cancer, the top five causes of cancer deaths among women between the ages of 50 and 69 years. A new decision-making process about participation in a trial and the involvement of healthcare professional figures to back-up the physicians - including research
nurses, case managers and psychologists - should be examined for an engagement model fostering clinical research.

Correct information, especially for less educated women with a shorter history of disease, must be carefully considered. Shared decision-making facilitates patient-centered care and is increasingly important in oncology, where patients are faced with multifaceted treatment decisions that require them to weigh efficacy and safety, quality of life, and cost. It needs time and effort from physicians and patients to communicate straightforwardly; communication barriers still exist between patients and physicians. The shared decision-making process with ovarian cancer patients has to be developed, while concentrating on understanding a patient’s fears, emotions and reactions better. Exploring patients’ psychological needs could help physicians boost their engagement in clinical research, and dedicated healthcare professionals would be particularly useful when patients experience high levels of distress which can create difficulties in decision-making about participation in a trial.

Patients’ associations, besides providing support and comfort by giving a sense of belonging and through mutual help, are important partners in clinical research, providing scientific information, promoting the culture of partnership and supporting the active participation of patients in decisions. The results of this research could be useful for advocate groups and clinicians to implement concrete actions for raising awareness on the importance of clinical research participation.

**Abbreviations**

ACTO, Alleanza contro il tumore ovarico Onlus, Alliance against ovarian cancer

MaNGO, Mario Negri Gynecologic Oncology

MITO, Multicenter Italians Trials in Ovarian Cancer

RCT, randomised clinical trials

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the Ethics Committee of the Institute Carlo Besta IRCCS as coordinator center (reference numbers 54/2018), and by the local ethics committees of all participant centers. The study protocol was also approved by the ACTO Scientific Committee. Each woman with ovarian cancer enrolled was required to sign written informed consent to enter the study. This report does not contain any personal information.

**Consent for publication**

All the authors meet the journal’s criteria for authorship and have read and approved the article.
Availability of data and material

The dataset analysed for this study are available from the corresponding author on reasonable request.

Competing Interest

PM, AR NCe, NC, FD, MDI, FAP, PS, GC, RC, MM, AMM, GGi, DG, AF, GR, GRi, CM, LG, GCo, GCS, AC, MP, GA, AF, ML, FT, and FS report no conflicts of interest.

DL, ML, GS, PV, SG, and PZ report have received as advisory board membership, speakers honoraria, travel support, research grants, consulting fees support from Astra Zeneca, Clovis Oncology, EISAI, GSK, Gentili, Genmab, Immunogen, Incyte, Johnson & Johnson, Leo Pharma, Lilly, Pharmamar, MSD, Merck Serono, Novartis, Pfizer, Roche, Tesaro.

Funding

This project was funded by ACTO Onlus, Alleanza contro il tumore Ovarico. ACTO was directly involved in all the phases of the project.

Authors' contributions

PM, NCe designed the study protocol; AR and PM analysed the database and NC, FD, MDI, DL, and FAP gave substantial contributions to the interpretation of findings; PM, AR, and FD drafted the manuscript; PS, GC, ML, GS, RC, MM, AMM, GGi, DG, PV, AF, GR, GRi, CM, SG, LC, GCo, GCS, AC, MP, GA, AF, ML, FT, PZ, and FS collected of data. All authors revised the manuscript and approved the final version.

Acknowledgements

1. Network of Clinicians Participants

Grazia Artioli, AULSS 3 Serenissima, Mirano VE;
Luigi Cavanna, AUSL, Piacenza;
Rita Ceccherini, Azienda Sanitaria Universitaria Integrata (ASUI), Trieste;
Giovanna Cirigliano, Ospedale S. Luca, Lucca;
Giuseppe Comerci, Ospedale S. Maria delle Croci, Ravenna;
Gennaro Cormio, Policlinico, Bari;
Alessandra Crippa, ASST di Lecco, Lecco;
Alberto Farolfi, IRCCS IRST, Meldola FC;
Antonio Febbraro, Ospedale Sacro Cuore di Gesù Fatebenefratelli, Benevento;
Donatella Giardina, Ospedale Ramazzini, Carpi;
Stefano Greggi, Istituto Nazionale dei Tumori, Napoli;
Maurizio Lalle, A.O. San Giovanni Addolorata, Roma;
Mariateresa Lapresa, Istituto Europeo di Oncologia, Milano;
Marina Marzola, AOU S. Anna, Ferrara;
Carla Merisio, AUO, Parma;
Anna Maria Mosconi, Ospedale S. Maria della Misericordia, Perugia;
Michele Peiretti, AOU Policlinico D. Casula, Monserrato CA;
Giuseppe Ricci, Institute for Maternal and Child Health, IRCCS 'Burlo Garofolo', Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste;
Graziana Ronzino, Ospedale Vito Fazzi, Lecce;
Giovanni Scambia, Fondazione Policlinico Gemelli, Roma;
Paolo Scollo, Ospedale Cannizzaro, Catania; Gennaro Cormio, Policlinico, Bari;
Federica Sina, Ospedale S. Gerardo, Monza MI;
Giulia Carlo Stella, Grande Ospedale Metropolitano Niguarda, Milano;
Federica Tomao, Istituto Europeo di Oncologia, Milano;
Patrizia Vici, Istituto Nazionale dei Tumori Regina Elena, Roma;
Paolo Zola, P.O. S. Anna-Città della Salute, Torino.

The authors thank Guya Sgaroni for organizational assistance, Silvia Radrezza for help preparing the questionnaire, and Judith Baggott for editorial assistance.

ACTO Regional headquarters: Puglia, Campania, Lombardia, Piemonte, Lazio.

References

1. Frisch N, Atherton P, Doyle-Waters MM, et al. Patient-oriented research competencies in health (PORCH) for researchers, patients, healthcare providers, and decision-makers: results of a scoping
review. Res Involv Engagem. 2020;6:4. 10.1186/s40900-40020-40180-40900. eCollection 42020. doi).

2. Mader LB, Harris T, Kläger S, Wilkinson IB, Hiemstra TF. Inverting the patient involvement paradigm: defining patient led research. Res Involv Engagem. 2018;4:21. 10.1186/s40900-40018-40104-40904. eCollection 42018. doi).

3. Castle JC, Chalmers I, Atkinson P, et al. Establishing a library of resources to help people understand key concepts in assessing treatment claims-The "Critical thinking and Appraisal Resource Library" (CARL). PLoS One. 2017;12(7):e0178666. doi: 0178610.0171371/journal.pone.0178666. eCollection 0172017.

4. Chalmers I, Atkinson P, Badenoch D, et al. The James Lind Initiative: books, websites and databases to promote critical thinking about treatment claims, 2003 to 2018. Res Involv Engagem. 2019;5:6. 10.1186/s40900-40019-40138-40902. eCollection 42019. doi).

5. Mosconi P, Antes G, Barbareschi G, et al. A European multi-language initiative to make the general population aware of independent clinical research: the European Communication on Research Awareness Need project. Trials. 2016;17:19. 10.1186/s13063-13015-11146-13067. doi).

6. Multi-ACT. Toolbox. https://toolbox.multiact.eu/.

7. S. P. EUPATI: An initiative to provide expertise in patient advocacy and in medicines development processes. https://www.eupati.eu/wp-content/uploads/2016/09/2013-09-Regulatory-Rapporteur-September-EUPATI_EN.pdfSeptember 2013.

8. Jenkins V, Farewell V, Farewell D, et al. Drivers and barriers to patient participation in RCTs. Br J Cancer. 2013;108(7):1402-1407. doi: 1410.1038/bjc.2013.1113. Epub 2013 Mar 1419.

9. Viljoen B, Chambers SK, Dunn J, Ralph N, March S. Deciding to Enrol in a Cancer Trial: A Systematic Review of Qualitative Studies. J Multidiscip Healthc. 2020;13:1257-1281. (doi):10.2147/JMDH.S266281. eCollection 262020.

10. World Ovarian Cancer Coalition. The Every Woman Study Summary Report. 2018.

11. Mathews C, Restivo A, Raker C, Weitzen S, Disilvestro P. Willingness of gynecologic cancer patients to participate in clinical trials. Gynecol Oncol. 2009;112(1):161-165. doi: 110.1016/j.ygyno.2008.1009.1003. Epub 2008 Oct 1025.

12. Meneguin S, Cesar LA. Motivation and frustration in cardiology trial participation: the patient perspective. Clinics (Sao Paulo). 2012;67(6):603-608. doi: 610.6061/clinics/2012(6006)6010.

13. Cox K, McGarry J. Why patients don't take part in cancer clinical trials: an overview of the literature. Eur J Cancer Care (Engl). 2003;12(2):114-122. doi: 110.1046/j.1365-2354.2003.00396.x.

14. Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. J Natl Cancer Inst. 2019;111(3):245-255. doi: 210.1093/jnci/djy1221.

15. Nielsen ZE, Berthelsen CB. Cancer patients' perceptions of factors influencing their decisions on participation in clinical drug trials: A qualitative meta-synthesis. J Clin Nurs. 2019;28(13-14):2443-2461. doi: 2410.1111/jocn.14785. Epub 12019 Mar 14783.
16. Truong TH, Weeks JC, Cook EF, Joffe S. Altruism among participants in cancer clinical trials. *Clin Trials*. 2011;8(5):616-623. doi: 610.1177/1740774511414444. Epub 1740774511412011 Aug 1740774511414443.

17. Boudewyns V, Southwell BG, DeFrank JT, et al. Patients’ understanding of oncology clinical endpoints: A literature review. *Patient Educ Couns*. 2020;103(9):1724-1735. doi: 1710.1016/j.pec.2020.1703.1018. Epub 2020 Mar 1720.

18. Staniszewska A, Lubiejewska A, Czerw A, et al. Awareness and attitudes towards clinical trials among Polish oncological patients who had never participated in a clinical trial. *Adv Clin Exp Med*. 2018;27(4):525-529. doi: 510.17219/acem/68762.

19. Reid F, Bhatla N, Oza AM, et al. The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. *Int J Gynecol Cancer*. 2021;31(2):238-244. doi: 210.1136/ijgc-2019-000983. Epub 002020 Jun 000914.

20. group MNGO. http://www.mango-group.it/.

21. Multicenter Italian Trials in. Ovarian cancer and gynecologic malignancies group. https://www.mito-group.it/.

22. Johnson CAN, Blazeby JM, Bottomley A, Fayers P, Koller M, Kuliś D, Ramage J, Sprangers M, Velikova G, Young T. *EORTC Guidelines for Developing Questionnaire Modules* Last access 24 Jun 2021 April 2011.

23. Burks AC, Doede A, Showalter SL, Keim-Malpass J. Perceptions of Clinical Trial Participation Among Women of Varying Health Literacy Levels. *Oncol Nurs Forum*. 2020;47(3):273-280. doi: 210.1188/1120.ONF.1273-1280.

24. National Academies of Sciences E, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Roundtable on Health Literacy; French MG, Wojtowicz A, editors. Health Literacy in Clinical Research: Practice and Impact: Proceedings of a Workshop. Washington (DC): National Academies Press (US). 3, Embedding Health Literacy in Clinical Trials to Improve Recruitment and Retention. 2020 May 28.

25. Morris NS, Field TS, Wagner JL, et al. The association between health literacy and cancer-related attitudes, behaviors, and knowledge. *J Health Commun*. 2013;18 Suppl 1(Suppl 1):223-241. doi: 210.1080/10810730.10812013.10825667.

26. Verkissen MN, Ezendam NP, Fransen MP, et al. The role of health literacy in perceived information provision and satisfaction among women with ovarian tumors: a study from the population-based PROFILES registry. *Patient Educ Couns*. 2014;95(3):421-428. doi: 410.1016/j.pec.2014.1003.1008. Epub 2014 Mar 1020.

27. Awwad O, Maaiah S, Almomani BA. Clinical trials: Predictors of knowledge and attitudes towards participation. *Int J Clin Pract*. 2021;75(3):e13687. doi: 13610.11111/ijcp.13687. Epub 12020 Sep 13621.

28. Kotowski A, Świetlik D, Kotowska M, Wronowski M, Fal AM. 1651P - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients: A pilot
9. Tang M, Joensuu H, Simes RJ, et al. Challenges of international oncology trial collaboration—a call to action. *Br J Cancer*. 2019;121(7):515-521. doi: 10.1038/s41416-019-04141-4. Epub 2019 Aug 1415.

30. Mazzocco K, Masiero M, Carriero MC, Pravettoni G. The role of emotions in cancer patients’ decision-making. *Ecancermedicalscience*. 2019;13:914. (doi):10.3332/ecancer.2019.3914. eCollection 2019.

31. Morgado P, Sousa N, Cerqueira JJ. The impact of stress in decision making in the context of uncertainty. *J Neurosci Res*. 2015;93(6):839-847. doi: 10.1002/jnr.23521. Epub 2014 Dec 23526.

32. Bishop SJ, Gagne C. Anxiety, Depression, and Decision Making: A Computational Perspective. *Annu Rev Neurosci*. 2018;41:371–88. 10.1146/annurev-neuro-080317-062007. Epub 2018 Apr 080325. doi).

33. Gorini A, Mazzocco K, Pravettoni G. Decision-Making Process Related to Participation in Phase I Clinical Trials: A Nonsystematic Review of the Existing Evidence. *Public Health Genomics*. 2015;18(6):359-365. doi: 10.1159/000441559. Epub 2015 Nov 000441554.

34. Lerner JS, Li Y, Valdesolo P, Kassam KS. Emotion and decision making. *Annu Rev Psychol*. 2015;66:799–823. 10.1146/annurev-psych-010213-115043. Epub 2014 Sep 010222. doi).

35. Treffers T, Putora PM. Emotions as Social Information in Shared Decision-Making in Oncology. *Oncology*. 2020;98(6):430-437. doi: 10.1159/000505341. Epub 2020 Jan 000505343.

36. Covvey JR, Kamal KM, Gorse EE, et al. Barriers and facilitators to shared decision-making in oncology: a systematic review of the literature. *Support Care Cancer*. 2019;27(5):1613-1637. doi: 1610.1007/s00520-00019-04675-00527. Epub 2019 Feb 00528.

37. Crocker JC, Ricci-Cabello I, Parker A, et al. Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ. 2018;363:k4738. 10.1136/bmj.k4738. doi).

38. Bhardwaj P, Kumar J, Yadav RK. Patients Driving the Clinical Trial Designs - Democracy in Clinical Research. *Rev Recent Clin Trials*. 2019;14(4):237-246. doi: 210.2174/1574887114666190808142339.

39. Forsythe LP, Frank LB, Hemphill R, et al. Researchers, Patients, and Stakeholders Evaluating Comparative-Effectiveness Research: A Mixed-Methods Study of the PCORI Reviewer Experience. *Value Health*. 2018;21(10):1161-1167. doi: 1110.1016/j.jval.2018.1103.1018. Epub 2018 Jun 1112.

40. Lee DJ, Avulova S, Conwill R, Barocas DA. Patient engagement in the design and execution of urologic oncology research. *Urol Oncol*. 2017;35(9):552-558. doi: 510.1016/j.urolonc.2017.1007.1002. Epub 2017 Jul 1026.

### Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
- Suppl01.docx
- Suppl02.docx